As of 2025-10-18, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -3.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 512.92 mil USD. RGNX's TTM EBITDA according to its financial statements is -148.75 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 18.3x | 16.4x |
| Forward P/E multiples | 31.7x - 54.4x | 48.7x |
| Fair Price | (91.84) - (52.38) | (94.29) |
| Upside | -883.0% - -546.5% | -903.8% |
| Date | EV/EBITDA |
| 2025-10-16 | -3.66 |
| 2025-10-15 | -3.64 |
| 2025-10-14 | -3.29 |
| 2025-10-13 | -3.32 |
| 2025-10-10 | -3.17 |
| 2025-10-09 | -3.60 |
| 2025-10-08 | -3.61 |
| 2025-10-07 | -3.03 |
| 2025-10-06 | -3.10 |
| 2025-10-03 | -3.01 |
| 2025-10-02 | -3.06 |
| 2025-10-01 | -2.78 |
| 2025-09-30 | -2.74 |
| 2025-09-29 | -2.81 |
| 2025-09-26 | -2.74 |
| 2025-09-25 | -2.64 |
| 2025-09-24 | -2.70 |
| 2025-09-23 | -2.50 |
| 2025-09-22 | -2.54 |
| 2025-09-19 | -2.48 |
| 2025-09-18 | -2.64 |
| 2025-09-17 | -2.53 |
| 2025-09-16 | -2.61 |
| 2025-09-15 | -2.55 |
| 2025-09-12 | -2.59 |
| 2025-09-11 | -2.69 |
| 2025-09-10 | -2.71 |
| 2025-09-09 | -2.82 |
| 2025-09-08 | -2.68 |
| 2025-09-05 | -2.76 |
| 2025-09-04 | -2.66 |
| 2025-09-03 | -2.81 |
| 2025-09-02 | -2.56 |
| 2025-08-29 | -2.50 |
| 2025-08-28 | -2.52 |
| 2025-08-27 | -2.46 |
| 2025-08-26 | -2.56 |
| 2025-08-25 | -2.51 |
| 2025-08-22 | -2.52 |
| 2025-08-21 | -2.22 |
| 2025-08-20 | -2.21 |
| 2025-08-19 | -2.19 |
| 2025-08-18 | -2.42 |
| 2025-08-15 | -2.46 |
| 2025-08-14 | -2.54 |
| 2025-08-13 | -2.50 |
| 2025-08-12 | -2.22 |
| 2025-08-11 | -2.00 |
| 2025-08-08 | -2.13 |
| 2025-08-07 | -2.15 |